Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
The FDA granted orphan drug exclusivity to Precigen's PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis (RRP). This regulatory designation provides seven years of market exclusivity in the US, effective through August 14, 2032.
Key figures
- Drug Name
- PAPZIMEOS (zopapogene imadenovec-drba)
- Exclusivity end date
- August 14, 2032
- Exclusivity duration years
- 7
- Us adult rrp patient count
- 27000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.